Contact this trialFirst, we need to learn more about you.
Estrogen Receptor Antagonist
Tucatinib + Trastuzumab for HER2-Positive Cancers
Recruiting1 awardPhase 2
Durham, North Carolina
This trial is for people with solid tumors that make too much HER2 or a different type of HER2. Participants will get tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get fulvestrant. The trial will look at side effects.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.